Acurx Pharmaceuticals, Inc. (ACXP): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:30 ET
- Event date
- 2026-11-12
- Accession no.
- 0001104659-26-127104
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Acurx discloses Joseph C. Scodari's retirement from the Board
Acurx Pharmaceuticals disclosed that Joseph C. Scodari notified the Company of his intention to retire from the Board, effective November 13, 2026. His decision did not result from any disagreement with the Company on its operations, policies or practices. He agreed to continue serving as a corporate advisor.
- Joseph C. Scodari's Board retirement is effective November 13, 2026.
- Scodari had served on the Board since 2021.
- His decision did not result from any disagreement with the Company on its operations, policies or practices.
- Scodari agreed to continue serving the Company as a corporate advisor.
board change
Items reported
- Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | tm2629685d1_8k.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.